New biotech Septerna emerges with $100 million financing

A new California, USA-based biotechnology company, named Septerna, has launched today with the aim of discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs).

Septerna starts life with a Series A financing of $100 million, that was led by Third Rock Ventures with significant support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital.

Septerna’s proprietary Native Complex Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment which enables industrial-scale drug discovery using novel screening technologies and structure-based drug design for the first time. Septerna is using the Native Complex to overcome historic challenges of reaching the vast untapped potential of GPCR drug targets for a wide range of diseases.